Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Autor: David Simon, Koray Tascilar, Gerhard Krönke, Arnd Kleyer, Mario M. Zaiss, Franz Heppt, Christine Meder, Raja Atreya, Entcho Klenske, Peter Dietrich, Abdullah Abdullah, Thorsten Kliem, Giulia Corte, Harriet Morf, Moritz Leppkes, Andreas E. Kremer, Andreas Ramming, Milena Pachowsky, Florian Schuch, Monika Ronneberger, Stefan Kleinert, Clara Maier, Axel J. Hueber, Karin Manger, Bernhard Manger, Carola Berking, Matthias Tenbusch, Klaus Überla, Michael Sticherling, Markus F. Neurath, Georg Schett
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Nature Communications, Vol 11, Iss 1, Pp 1-7 (2020)
Druh dokumentu: article
ISSN: 2041-1723
DOI: 10.1038/s41467-020-17703-6
Popis: Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are safe to continue and are possibly protective against COVID19.
Databáze: Directory of Open Access Journals